Start-Up Speed vs. Total Trial Success: Balancing RTSM Priorities

In the high-pressure environment of clinical trial startups, the promise of a four-week Randomization and Trial Supply Management (RTSM) build is an alluring prospect. However, focusing solely on the "speed to green light" often masks significant long-term risks. Since the build phase typically represents less than 5% of a trial’s total lifecycle, prioritizing initial velocity over architectural flexibility can lead to a "speed trap" of manual workarounds and costly delays when protocol amendments inevitably arise.

True efficiency isn't just about the timeline to go-live; it’s about lead time —the gap between contract award and actual resource deployment—and the system's ability to evolve. Rigid, standardized platforms may launch quickly but often lack the nuance required for complex protocols, resulting in "integration friction" within the broader eClinical ecosystem. By synchronizing RTSM development with EDC and supply chains, and prioritizing high-touch support models, sponsors can ensure their technology remains an asset rather than a liability throughout the years of production.